European Pharmaceutical Review

FEBRUARY 22, 2024

The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. Its mechanism of action is such that it reduces inflammation-causing enzymes and subsequent hair loss at the follicle, NICE explained. “I

85

85

European Pharmaceutical Review

SEPTEMBER 14, 2023

Rimegepant (Vydura) is the “first and only NICE-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment,” shared Helen Knight, Director of medicines evaluation at the National Institute for Health and Care Excellence (NICE).

100

100

European Pharmaceutical Review

OCTOBER 17, 2023

In final guidance , the National Institute for Health and Care Excellence (NICE) has recommended glofitamab as a new treatment option for advanced lymphoma. NICE “welcome the news that NHS England will make this available to patients quickly,” Knight added. According to NICE, over 700 people could benefit from Roche’s glofitamab.

FDA 105

FDA 105

pharmaphorum

MARCH 6, 2024

NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the UK will depend on a patient’s address.

105

105

pharmaphorum

JANUARY 18, 2024

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.

111

111

pharmaphorum

JANUARY 25, 2024

NICE firms up guidance backing NHS use of five digital health wearables for remote monitoring of Parkinson's disease patients

111

111

Hospital Pharmacy Europe

JANUARY 24, 2024

The poly ADP-ribose polymerase (PARP) inhibitor talazoparib (brand name Talzenna) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat a type of locally advanced or metastatic breast cancer. The trial did not show any difference in how long people live. So talazoparib is recommended.’

Chemotherapy 101

Chemotherapy Hospitals 101

pharmaphorum

MARCH 7, 2024

NICE decision on Ipsen’s Cabometyx and MSD’s Keytruda in first-line kidney cancer ends a disparity in access within the UK.

105

105

Hospital Pharmacy Europe

JANUARY 17, 2024

The National Institute for Health and Care Excellence (NICE) has recommended that empagliflozin can be used as an option for treating chronic kidney disease (CKD) in adults under some circumstances. NICE’s decision to include empagliflozin as an option in some patients with CKD means it must be made available within three months.

Hospitals 105

Hospitals 105

pharmaphorum

DECEMBER 21, 2023

NICE backs NHS use of digital COPD rehab programmes, myCOPD and SPACE for COPD, as an alternative to face-to-face consultations

111

111

pharmaphorum

NOVEMBER 21, 2023

New NICE Advice service Mike.Hammerton Tue, 21/11/2023 - 09:00 Bookmark this

116

116

Pharmafile

APRIL 9, 2024

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury (remdesivir) for the treatment of COVID-19 in eligible adults and children.

59

59

pharmaphorum

JANUARY 31, 2024

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9

112

112

European Pharmaceutical Review

JANUARY 19, 2024

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations.

Chemotherapy 85

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 85

pharmaphorum

MARCH 19, 2024

Do better: The message to the industry from an analysis of clinical evidence submitted to NICE over 20 years Mike.Hammerton Tue, 19/03/2024 - 09:24 Bookmark this

124

124

NICE

MARCH 7, 2024

At NICE, we’re celebrating the theme #InspireInclusion as we mark International Women’s Day 2024. Coming from a black ethnic background sitting on the NICE committee gives me the opportunity to contribute towards improving care and pregnancy outcomes in these women. My passion lies in global women’s health.

52

52

Outsourcing Pharma

FEBRUARY 22, 2024

The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.

97

97

pharmaphorum

JANUARY 11, 2024

NICE has extended the NHS availability of Pfizer’s COVID-19 drug Paxlovid as millions of doses approach their expiry date

105

105

Pharmaceutical Technology

JANUARY 22, 2024

The UK NICE recommends Pfizer's talazoparib, marketed as Talzenna, to treat a specific type of locally advanced or metastatic breast cancer.

98

98

European Pharmaceutical Review

DECEMBER 21, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone, for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy.

Chemotherapy 86

Chemotherapy Hospitals FDA 86

pharmaphorum

JANUARY 23, 2024

Two artificial intelligence-powered software tools – e-Stroke and RapidAI – have been recommended for use in the NHS to help detect stroke from CT brain scans by NICE.

Hospitals 110

Hospitals 110

Pharmafile

JANUARY 12, 2024

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients are eligible to access Paxlovid, this review increases the figure from 3.9 million people to 5.3 million people. million people at risk of severe COVID-19 appeared first on Pharmafile.

95

95

Pharmafile

MARCH 5, 2024

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) in combination with platinum-containing chemotherapy.

Chemotherapy 59

Chemotherapy 59

Hospital Pharmacy Europe

JULY 13, 2023

NICE appraised 70% more medicines in 2022/23 than in 2019/20, which has led to faster access to medicines, its chief executive has said. By simplifying, removing, or reconfiguring parts of the appraisals process, NICE said it can do light-touch, faster evaluations to simpler, low-risk treatments to speed up its guidance.

Hospitals 97

Hospitals 97

Outsourcing Pharma

FEBRUARY 6, 2024

An artificial intelligence (AI)-powered tool from UK-based Brainomix was one of only two products to be endorsed by health assessor the National Institute of Health and Care Excellence (NICE).

94

94

Hospital Pharmacy Europe

MARCH 9, 2023

NICE has recommended use of semaglutide with a reduced-calorie diet and increased physical activity as a therapeutic option for weight loss In a technology appraisal guidance, the UK’s NICE has recommended the use of semaglutide as part of a weight loss management strategy. billion and £27 billion to wider society. .’

Hospitals 98

Hospitals 98

pharmaphorum

NOVEMBER 20, 2023

NICE to consult on inflation-busting fee increases Mike.Hammerton Mon, 20/11/2023 - 09:55 Bookmark this

121

121

European Pharmaceutical Review

OCTOBER 26, 2023

The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s foslevodopa–foscarbidopa (Produodopa) as a treatment option for advanced Parkinson’s. This is the first technology appraisal from NICE to look at a treatment for Parkinson’s. The treatment is administered by an infusion pump over 24 hours.

64

64

Hospital Pharmacy Europe

AUGUST 24, 2023

A birch bark extract has been recommended by NICE for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa. Birch bark extract approval The extract represents the first treatment recommended by NICE for epidermolysis bullosa. vs 80.7%) although these were mainly of mild-to-moderate intensity.

Hospitals 98

Hospitals 98

European Pharmaceutical Review

MAY 19, 2023

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. Therefore, NICE’s final draft guidance for this indication is welcomed by the industry.

Hospitals 101

Hospitals 101

Pharmaceutical Technology

OCTOBER 27, 2023

The UK NICE has recommended the use of AbbVie’s foslevodopa–foscarbidopa (Produodopa) for the treatment of advanced Parkinson’s disease.

98

98

pharmaphorum

OCTOBER 26, 2023

NICE backs pump-based Parkinson’s drug from AbbVie Phil.Taylor Thu, 26/10/2023 - 10:14 Bookmark this

115

115

Pharmaceutical Technology

SEPTEMBER 8, 2023

The UK NICE has recommended Eli Lilly’s tirzepatide for the treatment of adult patients with inadequately controlled type 2 diabetes.

98

98

Hospital Pharmacy Europe

FEBRUARY 27, 2024

The Janus kinase (JAK) inhibitor ritlecitinib has been recommended by NICE for the treatment of severe alopecia areata in adults and children aged 12 and over. NICE said the position had changed after a public consultation, additional information from the drug manufacturer Pfizer and an improved discount on the cost of the medicine.

Hospitals 52

Hospitals 52

pharmaphorum

MAY 20, 2022

After a non-committal appraisal of Big Health’s Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in favour of the digital therapy. ” The post Sleepio app for insomnia backed by NICE appeared first on.

Documentation 122

Documentation 122

Pharmaceutical Technology

JUNE 1, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer ’s rimegepant (Vydura) to prevent migraine attacks. NICE medicines evaluation director Helen Knight said: “Each year, the lives of millions of people in England are blighted by migraine attacks.

98

98

European Pharmaceutical Review

SEPTEMBER 8, 2023

National Institute for Health and Care Excellence (NICE) final draft guidance recommends tirzepatide as a new treatment option for this indication. The post NICE recommends new type 2 diabetes treatment appeared first on European Pharmaceutical Review.

FDA 98

FDA 98